Full-Time

Senior Director

Safety Assessment

Posted on 8/19/2025

Altasciences

Altasciences

1,001-5,000 employees

Integrated CRO for early-phase drug development

No salary listed

Columbia, MO, USA

In Person

Category
Lab & Research (5)
, , , ,
Requirements
  • PhD in relevant biomedical field; MD, DVM or Masters degree in combination with appropriate training and experience considered
  • 7+ years related experience in preclinical safety and toxicology evaluation in CRO or similar industry
  • 5+ years conducting, developing, and managing preclinical safety and efficacy programs
  • Experience in writing and presenting preclinical safety reports to support regulatory submissions
  • 8 years related experience and/or training; or equivalent combination of education and experience in industry/CRO drug development
  • 3+ years in a supervisory role
  • Advanced computer skills including Microsoft Office suite
  • English proficiency required to read, analyze, and interpret scientific and technical journals, financial reports, and legal documents; to respond to common inquiries or complaints from customers, regulatory agencies, or members of the business community; to write speeches and articles for publication that conform to prescribed style and format.
  • Excellent written and verbal communication skills including the ability to create and present high-quality scientific presentations
  • Advanced mathematical and statistical skills related to scientific and business data for interpretation and presentation to staff and upper management
  • Demonstrated ability to lead people and get results through others
  • Organize and manage multiple priorities
  • Problem analysis and problem resolution at both a strategic and functional level
Responsibilities
  • Is responsible for the overall direction, coordination, and evaluation of the department.
  • Mentors staff regarding drug development requirements, client management, and study design.
  • Leads the Good Laboratory Practices (GLP) compliance initiatives within the department.
  • Serves as an alternate for Test Facility Management responsibilities as assigned.
  • In conjunction with other site leadership, develops and implements strategic plans, new capabilities, policies and procedures to ensure department programs will meet or exceed internal and external customers’ needs and expectations.
  • Plans and directs activities to ensure use of best practices, process improvements and operational efficiency.
  • Assures the development, review, revision, and implementation of training material for the Safety Assessment team to support the attainment of scientific and regulatory excellence.
  • Ensures appropriate scientific review of study protocols, reports and other deliverables.
  • Serves as a scientific expert for studies during audits, on project teams, committees, and other assignments.
  • Carries out supervisory responsibilities in accordance with the organization's policies and applicable laws and is responsible for performance management of direct report(s).
  • Ensure appropriate designation of Study Directors to meet study objectives and prompt replacement of the Study Director if it becomes necessary to do so during the conduct of a study.
  • Participates in client meetings to support business development and client management activities.
  • Acts as company representative to regulatory agencies, including the FDA, and local regulatory agencies.
  • In conjunction with administrative personnel, reviews activity, operating, and budget reports to guide and direct programs or operations as required.
Desired Qualifications
  • DABT certification preferred

Altasciences provides an integrated CRO that handles the full early‑phase drug development path, from preclinical testing through clinical proof of concept and into manufacturing. Its approach combines discovery support, safety testing, clinical trial execution, and in‑house manufacturing to run programs under one roof. This contrasts with competitors that require pharma and biotech clients to source services from multiple vendors, adding complexity and risk; Altasciences streamlines the process by coordinating all steps. The company aims to help innovator drug programs move quickly and efficiently, delivering integrated data to de‑risk decisions and speed progression to later stages.

Company Size

1,001-5,000

Company Stage

Early VC

Total Funding

$6.7M

Headquarters

Laval, Canada

Founded

1976

Simplify Jobs

Simplify's Take

What believers are saying

  • Biotech/pharma consolidation demand for single-vendor early-phase development solutions increases.
  • 3D tissue technology adoption reduces animal testing costs and accelerates regulatory approval timelines.
  • Geographic footprint and participant database enable rapid enrollment for mid-size biopharma sponsors.

What critics are saying

  • Novo Holdings divesting Altasciences signals poor financial performance and operational cutbacks.
  • Charles River aggressive pricing on integrated packages captures 20% mid-size biopharma contracts.
  • AI-driven preclinical platforms from Insilico Medicine displace traditional animal safety pharmacology testing.

What makes Altasciences unique

  • Integrated CRO/CDMO spanning preclinical safety testing through Phase IV bioanalysis and manufacturing.
  • 9 North American facilities with 500,000+ participant database conducting 285+ trials annually.
  • VoxCell partnership integrates 3D tissue technology for human-relevant preclinical testing.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Employee Assistance & Telehealth Programs

Remote Work Options

Company News

GlobeNewswire
Mar 16th, 2026
Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note

ISELIN, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard...

Business Wire
Aug 20th, 2025
Altasciences Receives EcoVadis Gold Medal for Environmental, Social, and Governance (ESG) Efforts

EcoVadis, the world's most trusted provider of business sustainability ratings, has collaborated closely with Altasciences to enhance its environmental, social, and governance (ESG) initiatives, underscoring the company's commitment to a sustainable future and a reduced environmental footprint.

Yahoo Finance
Jul 31st, 2025
Altasciences and VoxCell BioInnovation Announce Strategic Collaboration to Advance Preclinical Drug Development

This partnership combines Altasciences' comprehensive early-phase drug development capabilities with VoxCell's cutting-edge 3D tissue technology to offer a more predictive and human-relevant preclinical testing environment.

Postmedia Network
Mar 28th, 2025
Altasciences Receives 2025 CDMO Leadership Award in Small Molecule Dosage Form Category

For 14 years, Outsourced Pharma's CDMO Leadership Awards have recognized the top-performing contract development and manufacturing organizations based on comprehensive industry research, and feedback from sponsors.

BioSpace
May 29th, 2024
Altasciences Receives 2024 CRO Leadership Award for Capabilities

Altasciences receives 2024 CRO Leadership Award for Capabilities.

INACTIVE